CNTB: Rademikibart showed rapid, significant FEV1 improvement and reduced treatment failures in acute asthma
The Seabreeze STAT asthma study showed rademikibart rapidly improved airway function and reduced treatment failures, with a significant FEV1 benefit at day 7. The drug was well-tolerated, and plans are underway to propose FEV1 improvement as a phase III endpoint for acute asthma.Based on Connect Bi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.